CDMO Market Poised for 7.25% CAGR Growth by 2032, According to DelveInsight

DelveInsight's report, "Contract Development Manufacturing Organization Market Insights, Competitive Landscape and Market Forecast-2032," offers detailed insights into current and future market trends, technological advancements, key challenges, growth drivers, and barriers. It also highlights major emerging offerings and profiles key CDMO companies shaping the market.

DelveInsight's analysis indicates that the Contract Development and Manufacturing Organization (CDMO) market is expanding rapidly, driven by the rising burden of chronic diseases such as cancer, cardiovascular disorders, and diabetes, which is increasing demand for advanced therapeutics. The growing reliance on biologics and small molecules-key in treating complex conditions-is further encouraging pharmaceutical and biotech companies to outsource development and manufacturing. Additionally, mergers, acquisitions, partnerships, and capacity expansion efforts by major CDMO providers are strengthening global capabilities. These combined factors are expected to significantly boost the adoption of outsourced, scalable, and efficient drug development services between 2025 and 2032.

To know more about why North America is leading the market growth in the Contract Development Manufacturing Organization market, get a snapshot of the report Contract Development Manufacturing Organization Market Trends - https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

CDMO Overview
A Contract Development and Manufacturing Organization (CDMO) offers end-to-end services to pharmaceutical and biotechnology companies, including drug development, manufacturing, packaging, and regulatory support. These organizations enable clients to move products from concept to commercialization more efficiently by providing expertise, infrastructure, and compliance-ready processes.
According to DelveInsight, the global CDMO market was valued at USD 233.71 billion in 2024 and is anticipated to reach USD 407.09 billion by 2032, growing at a 7.25% CAGR from 2025 to 2032.

Contract Development Manufacturing Organization Market Insights
North America is projected to dominate the CDMO market in 2024 due to the increasing prevalence of chronic diseases, including cancer and tuberculosis. As CDMOs offer process optimization, cost reduction, faster turnaround, and improved efficiency, more pharmaceutical and biotechnology companies are turning to outsourcing. This trend is expected to accelerate further through 2025-2032.

To read more about the latest highlights related to Contract Development Manufacturing Organization, get a snapshot of the key highlights entailed in the Contract Development Manufacturing Organization - https://www.delveinsight.com/sample-request/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Developments in the CDMO Market
• May 2025: Lupin Manufacturing Solutions (LMS) announced a strategic transformation to strengthen its CDMO offerings by investing in advanced therapeutic platforms and leveraging India's API ecosystem.
• May 2025: VGXI, Inc. completed a successful US FDA inspection of its GMP facility, leading to the approval of a client's Biologics License Application (BLA), reinforcing its quality and regulatory excellence.
• May 2025: Tivic Health® Systems, Inc. partnered with Scorpius BioManufacturing to finalize GMP validation for EntolimodTM, its lead ARS candidate, ahead of an FDA BLA submission.
• March 2025: Ayrmid Pharma Ltd. and RoslinCT launched a partnership to manufacture the cell therapy Omisirge, marketed in the US by Gamida Cell Inc.
• February 2022: Asymchem Inc. agreed to acquire Snapdragon Chemistry for USD 57.94 million to enhance its US presence and strengthen early-stage chemical process development.
• February 2022: MilliporeSigma completed its USD 780 million acquisition of Exelead, expanding its CDMO capabilities in the mRNA therapeutic space.
These strategic moves are expected to propel the CDMO market's growth during the forecast period.

Key Contract Development Manufacturing Organization Companies
Major players in the global CDMO market include Patheon (Thermo Fisher Scientific), Catalent, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne, EMERGENT, Onyx Scientific, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, WuXi Biologics, and others.
Explore emerging leaders and market influencers in the complete report.

Which MedTech key players in the Contract Development Manufacturing Organization market are set to emerge as the trendsetter explore @ Key Contract Development Manufacturing Organization Companies - https://www.delveinsight.com/sample-request/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contract Development Manufacturing Organization Market Landscape Assessment
CDMOs are scaling their capabilities by investing in state-of-the-art biologics manufacturing facilities, increasing production capacity, and acquiring niche specialists. These efforts are expanding their service portfolios and reinforcing their roles as critical partners in the biopharmaceutical supply chain. For instance, Agilent Technologies' acquisition of Biovectra for USD 925 million in July 2024 significantly enhanced its biologics, potent API, and gene-editing manufacturing capacities-strengthening its position in the CDMO space. Such advancements continue to propel the biologics segment and fuel overall market expansion.

Contract Development Manufacturing Organization Market Report Scope
• Coverage: Global
• Study Period: 2022-2032
• CDMO Market Segmentation by Drug Type: Small Molecules, Biologics
• CDMO Market Segmentation by Service Type: API, Finished Drug Products
• CDMO Market Segmentation by Form Type: Solids, Liquids
• CDMO Market Segmentation by Manufacturing Type: Clinical Manufacturing, Commercial Manufacturing
• Geographic Segmentation: North America, Europe, Asia-Pacific, Rest of World
• Key CDMO Companies: Patheon, Catalent, Cambrex, Recipharm, Merck & Co., AGC Biologics, Lonza, Samsung Biologics, FUJIFILM Diosynth, and others
• Includes: Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL Insights, and Analyst Perspectives.

Download sample report now @ https://www.delveinsight.com/sample-request/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

D21 Corporate park, Dwarka

About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences sector. It supports pharmaceutical companies with comprehensive strategic solutions, helping them improve performance, gain actionable insights, and accelerate growth. Its healthcare consulting services enable clients to navigate market challenges and capture emerging opportunities with a practical, data-driven approach.

This release was published on openPR.